All Type of News
LG Life Sciences to conduct phase I trial of novel diabetic agent
LG Life Sciences announced on October 25 that it will conduct Phase I test of a new dipeptidyl peptidase IV (LC15-0444) for the treatment of type II diabetes.
In type II diabetes, either the pancreas does not produ...
Korean government criticized for concession on U.S.'s easier marketRepresentatives of the Korea Pharmaceutical Manufacturers Association (KPMA), who held a press conference on October 24 in Seoul, criticized the Korean government for its conces...
|
KPTA calls for well-prepared drug policy in KORUS talks
The Korea Pharmaceutical Manufacturers Association (KPMA) has urged the government to establish more well-prepared drug measure in the ongoing free trade agreement (FTA) talks with the United States, as the government...
Dong-A Pharm to export Zydena to Saudi ArabiaDong-A Pharmaceutical Co. Ltd. said recently it will export Zydena (udenafil), a new phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction (ED), to Saudi Arabia.
...
|
Prof. Kang's phase 3 study on Nexava attracting world interests.
Prof. Kang Yun-kyu, the oncologist of Seoul Asan Hospital who was reputed with the anti-cancer drug therapy presented his paper titled "A new paradigm of anti-cancer therapy" covering his clinical studies on Nexava, a...
Daiho anti-cancer drug jointly to conduct clinical phase II studies in Korea.
A local clinical study on a new anti-cancer drug for the treatment of metastatic breast cancer patients starting from Oct. 23.
McChem Health and Yonsei University Cancer Center jointly reported on Oct. 23 that a ph...
KFDA criticized for anti-obesity medicine license
A lawmaker took issue with the Korea Food and Drug Administration's license withdrawal of Hanmi Pharm's anti-obesity drug Slimmer in the annual parliamentary audit on October 23, criticizing the health regulator's lac...
Storage regulation of bioequivalence test data in controversy
A lawmaker recently claimed the current notice of the Korea Food and Drug Administration (KFDA) on the storage of bioequivalence test data might be a culprit associated with the generic drug's efficacy fabrication.
...
Adulterated drugs to scrap starting from April next year.
The pharmaceutical affairs act will be revised for any adulterated drugs to scrap starting from April next year, and for this program the KFDA plans to develope a computer soft program of recalling and disposing the a...
Ahngook Pharm to publish Korea version of JACC next monthAhngook Pharm said on October 19 it will publish the first version of the Journal of the American College of Cardiology (JACC), the official journal of the American College of C...
|
